Introduction {#sec1-1}
============

CNS damage is one of the common complications of anticancer therapy in patients with ALL. Intrathecal chemotherapy and cranial irradiation are used as preventive measures for CNS leukemia development. These therapeutic options are used separately or in a combination depending on a particular therapy protocol.^[@ref1]^

Side effects of intrathecal administration of chemotherapeutic drugs and systemic chemotherapy are determined by pharmacogenetics and the kinetics of cytostatic drugs. Leukoencephalopathy is a characteristic complication caused by the intrathecal administration of Methothrexate, Cisplatinand, Cytarabine and Carmustine.^[@ref2]^ Toxic effects induced by Methothrexate are the most common in pediatric patients with leukemia. neurotoxicity can be divided into early and late leukoencephalopathy. Marked neurologic symptoms with minimal morphological changes on MRI images are typically registered during the acute phase of CNS damage. ^[@ref3]^ White matter changes seen on MRI in such cases can be reversible.^[@ref4]^ Clinical presentation may vary from insignificant symptoms to significant neurological deficit.^[@ref5]^ Late methothrexate-leukoencephalopathy develops more slowly and ultimately results in permanent focal neurological deficits. Periventricular and central white matter is involved primarily (signal intensification on T2-weighted MR images), while subcortical U-fibers remain relatively unaffected.^[@ref6]^ As a rule, the corpus callosum and the anterior commissure remain unchanged. These changes may be unilateral, bilateral, or ultimately, alternating between the two over the course of the disease. Typically, changes in the white matter MRI signal disappear sometime after the end of therapy, but may remain for the rest of a patient's life and may be accompanied by secondary nonspecific changes (gliosis and moderate ventricular dilatation).^[@ref7]^

Cranial irradiation side effects can be categorized into acute, early-delayed and late toxicity. Acute toxicity from cranial irradiation occurs within days or at most first few weeks of therapy. Clinically it is characterized by nausea, vomiting, headaches and cerebral edema. These complications are usually self-limiting. Earlydelayed (subacute) effects occurs within 3 months after end of irradiation. The clinical symptoms are similar to the acute toxicity with headaches, fatigue, irritability, anorexia, nausea and vomiting. These two types of radiation toxicity are not frequent for patients with leukemia, because in this case the total radiation dose is wellfractioned. Late toxicity occurs after 90 days after irradiation and has various presentations and most of them are irreversible. Most common complications are leukoencephalopathy, vascular toxicity (microhemorrhages, moyamoya pattern, radiation induced vascular malformations, mineralizating microangiopathy) and secondary tumors (meningiomas, gliomas, sarcomas). Radiographic presentation of radiation leukoencephalopathy is quite the same as in patients after intrathecal chemotherapy with leukoencephalopathy.^[@ref8],[@ref9]^ Even though the MR-appearance of chemo- and radiotherapy side effects on the adult brain has been known for quite a while, the detection of CNS damage in children in the setting of incomplete myelination and ongoing formation of neural connections remains a radiodiagnostic challenge.^[@ref10]^ It is known that with an increase in the time, that has passed since the end of therapy, there is a tendency to an increase in the manifestations of neurotoxicity. ^[@ref11],[@ref12]^ For example, it was evaluated the risk factors for stroke in a big cohort of 5- year survivors of childhood cancer who were followed up for a median time of 26 years, and it was proved the correlation between the incidence of stroke and received dose during cranial irradiation.^[@ref13]^ Therefore, antitumor therapy has a longterm impact on CNS and it is very important to obtain data on the morphofunctional status of CNS to correctly understand children's neurocognitive and psychological impairments. In this case, brain MRI could be a good method to predict further neurocognitive deficits at the period of rehabilitation and follow-up. But the correlation between visualized changes on brain MRI and neurocognitive functions is poorly studied yet.^[@ref14]^ In the context of increasing survivors' quality of life, the diagnosis and evaluation of post-therapeutic CNS damage and the development of rehabilitative and corresponding therapeutic measures are one of the top priorities in modern Pediatric Oncology.^[@ref15]^

Objectives {#sec2-1}
----------

The systematization of brain MRI changes in children who have completed therapy in accordance with the protocol including intrathecal chemotherapy or cranial irradiation as the method of prevention of CNS leukemia.

The correlation between the method of CNS prevention and the characteristics of MRI presentation of leukoencephalopathy.

This research is also an attempt to find out the correlation between early neurotoxic changes in brain MRI and neurocognitive functions impairments.

Materials and Methods {#sec1-2}
=====================

Patients {#sec2-2}
--------

Clinical data were updated on 01.11.2017. This is an observational study without control groups. In the study, we analyzed brain MRI results in 48 patients with ALL from the intermediate-risk group aged 2 to 15 years. According to the ALLMB- 2008 therapy protocol, all patients from the intermediate-risk group were randomized into two arms of CNS leukemia prevention therapy prior to the beginning of consolidation-II ([Figure 1](#fig001){ref-type="fig"}).

In one randomization arm (28 patients), as a means of CNS leukemia prevention, six additional intrathecally-administered doses of chemotherapeutic agents (Methotrexate, Cytarabine and Prednisolone) were performed, without any cranial irradiation (ARM-1). Another randomization arm (20 patients) involved additional cranial irradiation, with the total dose of 12 Gy (ARM-2). The radiation fields included retro-orbital regions, the base of the skull as well as the deep regions in the area of the middle cranial fossa. The daily dose must be 1 Gy on Day 1 and 1.7 Gy on the following days. Irradiation was performed 5 days a week until the appropriate cumulative dose is reached.

The clinical characteristics of these 48 patients reflected the whole group of patients included in ALL-MB-2008 protocol ([Table 1](#table001){ref-type="table"}). All patients included in the study were in remission according to the recent data. History taking, and medical documentation processing revealed no premorbid CNS illnesses. The mean age of children at the beginning of the therapy was 7 years old (varied from 2 to 15) and it was the same at the both groups of patients.

![Consolidation phase of ALL-MB-2008. The intermediate-risk group.](hr-11-3-7946-g001){#fig001}

###### 

Initial characteristics of the patients.

  Characteristics            Group with brain MRI   All patients included in ALL-MB-2008         
  -------------------------- ---------------------- -------------------------------------- ----- ------
  Sex                                                                                            
      Male                   20                     41.7                                   554   58.8
      Female                 27                     56.3                                   389   41.2
  Age                                                                                            
      \<10 years             36                     75                                     711   75.4
      10-15 years            12                     25                                     163   17.3
      \>15 years             0                      0                                      69    7.3
  White blood cells, ×109/                                                                       
      \<50                   36                     75                                     655   69.5
      \>50                   12                     25                                     288   30.5
  Spleen                                                                                         
      \<4 cm                 16                     33.3                                   298   31.6
      \>4 cm                 32                     66.7                                   645   68.4
  Immunophenotype                                                                                
      Non-T-ALL              33                     68.8                                   685   72.6
      T-ALL                  15                     31.2                                   258   27.4
  Total                      48                                                            943    

Imaging {#sec2-3}
-------

In 2014, after completion remission in consolidation phase, the patients underwent a course of rehabilitation at the Rehabilitation Research Centre "Russkoe Pole" of the "Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology". That time the MRI study of brain was carried out with various timing after the completion of consolidation. MRI was performed on average 26 months after the end of the consolidation phase (varied from 9 days to 56 months; 21 months for cranial irradiation group and 31 months for intrathecal chemotherapy group).

MRI was performed on Philips Achieva 3T. The scanning protocol included T1 3D FRFSE, Axial T2 FLAIR, Axial T2 FRFSE, SWI, Axial DWI, Sagittal T2 FRFSE. No contrast enhancement was performed. During the analysis of the obtained data, the following parameters were assessed: the thickness and folding of the cortex of the cerebral hemispheres and cerebellum as well as the existence of foci therein; the presence or absence of white matter damage as well as its type (focal or diffuse).

Neurocognitive tests {#sec2-4}
--------------------

Neurocognitive function in patients tested at the same time as the MRI was performed. Thу test system included tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control. Comparative groups were children who received only intrathecal chemotherapy and did not receive prophylactic radiation. The following techniques were used to assess cognitive functions and behavior: CANTAB eclipse (Cambridge Cognition) hardware and software complex test battery, T. Achenbach questionnaire (Child Behavior Checklist, CBCL), M. Kovach Child Depression Inventory, CDI.^[@ref16]^

Statistics {#sec2-5}
----------

The estimation of the data was carried out by the methods of multiple regression analysis, assessed the complex effect of several factors on the dependent variables of interest. All statistical calculations were performed using the STATISTICA program (by StatSost).

Results {#sec1-3}
=======

Imaging {#sec2-6}
-------

According to the MRI, areas of leukoencephalopathy were detected in 10 (50%) out of 20 children, who received radiotherapy (ARM-2). Focal changes in white matter of cerebral hemispheres were found in 8 (80%) out of these 10 cases ([Figure 2](#fig002){ref-type="fig"}), whereas the combination of diffuse and focal areas was registered in 2 patients (20%) (P=0.095). In 3 (30%) patients foci of leukoencephalopathy were localized just in one area (frontal or parietal) and two or more areas were involved in 7 patients (70%).

As for patients, who received additional intrathecal injections of chemotherapeutic agents (ARM-1), MRI signs of leukoencephalopathy were found in 17 (66.6%) out of 27 of them (one patient was excluded) (P=0.095). Focal involvement of the white matter of the cerebral hemispheres was detected in 12 (70.6%) out of these children, diffuse involvement - 3 patients (17.6%) and the combination of diffuse and focal areas was registered in 2 patients (11.8%) ([Figure 3](#fig003){ref-type="fig"}). All results of MRI studies are shown in [Table 2](#table002){ref-type="table"}.

Thus, white matter changes in brain were registered in 10 (50%) patients after combined-modality treatment (ARM-2) and in 17 (66.6%) patients after course with extra intrathecal chemotherapy (ARM-1). A statistical analysis of the correlation the existence of white matter lesions and the method of CNS leukemia prevention (intrathecal chemo- or radiotherapy) was made. Base on the multiple regression model, there was no correlation between these factors (P\<0.076).

Follow up of the patients' checked 2 of them with relapse. One patient, who received cranial irradiation, developed isolated testicular relapse. He was not excluding from the study group, as a repeat CSF examination did not reveal pathological cytosis and specific CNS involvement.

Imaging of excluded patient {#sec2-7}
---------------------------

It was detected that one patient with intrathecal chemotherapy had diffuse damage to the white matter of the cerebral hemispheres and the cerebellum as well as the damage to the cortex of the cerebral hemispheres, the pons and the cerebral peduncles. Apart from that, this patient had multiple foci of leukoencephalopathy, MRappearance of which complied with multiple intracerebral microhemorrhages. Two years later, this patient developed isolated CNS relapse with damage localization in the optic disk. At relapse, no dynamics of leukoencephalopathy and microhemorrhages were found. The patient was excluded from the analysis owing to ambiguous interpretation of MR-phenomena.

![Changes in a patient, who received radiotherapy. Axial FLAIR image (a,b). Axial T2 image (c). Changes are shown by arrows.](hr-11-3-7946-g002){#fig002}

Neurocognitive tests {#sec2-8}
--------------------

By the time the tasks of screening tests were performed (for visual-motor coordination and understanding of instructions), both studied groups showed lower indices compared to the norm. During the passage of the main series of tests, which included tests for visual, spatial and working memory, as well as planning tests, statistically reliable results were obtained only on the working memory test: participants, who did not undergo irradiation, had more productive working memory, compared with participants who have undergone irradiation (P=0.095). When assessing the emotionalbehavioral sphere, the combined clinical group differed from the norm in almost all indicators (P=0.095). According to the results of the questionnaire of T.Achenbach, there was no difference between the groups (P\<0.076). This picture indicates behavioral difficulties in children in the clinical group, regardless of the type of treatment. According to the M.Kovach children's depression questionnaire, no statistically significant differences between the groups were find.

In addition, there was no statistically based correlation between cognitive impairments and the degree of brain damage according to brain MRI (P\<0.076).

Discussion and Conclusions {#sec1-4}
==========================

Analysis of brain MRI data in patients did not reveal significant differences in radiographic presentation of leukoencephalopathy between patients who received craniocerebral irradiation and who received additional intrathecal injections of chemotherapeutic drugs. Leukoencephalopathy was found in about half of the patients. It was mostly diffuse and localized predominantly in the frontal and temporal lobes.

According to our data, the exclusion of radiation therapy from the treatment protocol of children with ALL did not have advantages over the use of additional intrathecal injections of cytotoxic drugs as prevention of leukemia from the point of view of changes on MRI. The analysis did not show significant differences in brain damage and severity of cognitive impairment depending on the type of prevention of CNS leukemia. Moreover, in this study, no statistical correlation was found between MRI leukoencephalopathy and neurocognitive impairment according to clinical tests data. At the time of the examination, patients were at different stages of rehabilitation, and the period after the end of therapy varied (from 9 days to 56 months). This detail is important because some patients may be at the stage of acute toxic changes, and some at the stage of late toxic effects. This study did not take into account such important effects of radiation therapy as the development of secondary tumors, neuroendocrine effects, the risk of vascular complications and late neurocognitive deficit. Perhaps the most promising is the use of modern methods for assessing brain activity and delicate brain structures (functional MRI, image diffusion tensor), which seems to be reasonable in this category of patients. Since the routine MRI performed even with at the scanner with an ultra-high magnetic field strength, does not provide information about possible damage at the level of pathways and functional centers.^[@ref17]^ For example, innovative visualization of tensor diffusion (tractography), carried out in children before and after chemotherapy, revealed a decrease in conductivity through the internal capsule emitting the crown and the body of the colosseum.^[@ref18]^

Thus, further comprehensive study of the late neurotoxic effects of radiation therapy and intrathecal chemotherapy is promising, given that the toxic effects of radiation and chemotherapeutic agents in addition to acute damage have long-term effects. These toxic effects occur over time, so prospective studies with a long observation period are needed. Despite the lack of statistical differences in the toxicity of prophylactic methods of CNS leukemia in our study, there will be further development of effective methods for diagnostics and therapy of toxic brain damage in children. Patients from this study will be included in prospective studies, with repeated MRI using innovative methods and clinical examinations, including a full neurocognitive assessment.

###### 

The results and analysis of brain MRI.

                                                      Group with additional lumbar punctions (%)   Group with cranial irradiation (%)
  --------------------------------------------------- -------------------------------------------- ------------------------------------
  Incidence of leukoencephalopathy                    17 (66.6)                                    10(50)
  Size (% out of all patients with lesions)                                                        
      Only focal                                      12 (70.6)                                    8(80)
      Only diffuse                                    3 (17.6)                                     0
      Combination of focal and diffuse lesions        2 (11.8)                                     2(20)
  Localization (% out of all patients with lesions)                                                
      Frontal                                         13 (76.4)                                    8(80)
      Temporal                                        6 (35.3)                                     2(20)
      Parietal                                        13 (76.4)                                    9(90)
      Occipital                                       9 (52.9)                                     2(20)
  Spread (% out of all patients with lesions)                                                      
      One lobe                                        5 (29.4)                                     3(30)
      Two or more lobes                               12 (70.6)                                    7(70)

![Changes in a patient, who received intrathecal chemotherapy. Axial FLAIR image. Changes are shown by arrows.](hr-11-3-7946-g003){#fig003}
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